ADVERTISEMENT
ADVERTISEMENT

INTENTLY FOCUSED

By David SchoonmakerINTENTLY FOCUSEDDemonstrating the power of combining scientific curiosity with product safety. STEVE PETTEWAYJASON VARNEY | VARNEYPHOTO.COM Stephen R. Petteway, Jr. regularly asks himself, "If I were a patient, what would I want to see in my products?" Unmet patient needs are his primary motivator, and he encourages the same attitude among the roughly 330 scientists, engineers, and technicians he directs at Talecris Biotherapeutics'

David Schoonmaker
STEVE PETTEWAY
JASON VARNEY | VARNEYPHOTO.COM

Stephen R. Petteway, Jr. regularly asks himself, "If I were a patient, what would I want to see in my products?" Unmet patient needs are his primary motivator, and he encourages the same attitude among the roughly 330 scientists, engineers, and technicians he directs at Talecris Biotherapeutics' plant in Clayton, NC, as well as its research and testing laboratories in Raleigh and Research Triangle Park. With more than 25 years in the pharmaceutical business, the last 11 of them with Bayer and Talecris, he brings a wealth of knowledge and experience to developing protein therapies, and moving them out of the lab and safely into the clinic as quickly as possible.

Known in the scientific community for pioneering work on HIV and pathogen safety in blood plasma-based medicines, Petteway...

Interested in reading more?

Magaizne Cover

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?
ADVERTISEMENT